References of "Boonen, A"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPatients' preferences for anti-osteoporosis drug treatment: A cross-European discrete choice experiment
Hiligsmann, M.; Dellaert, B. G.; Dirksen, C. D. et al

in Rheumatology (United Kingdom) (2017), 56(7), 1167-1176

Objectives. To estimate the preferences of osteoporotic patients for medication attributes, and analyse data from seven European countries. Methods. A discrete choice experiment was conducted in Belgium ... [more ▼]

Objectives. To estimate the preferences of osteoporotic patients for medication attributes, and analyse data from seven European countries. Methods. A discrete choice experiment was conducted in Belgium, France, Ireland, the Netherlands, Spain, Switzerland and the UK. Patients were asked to choose repeatedly between two hypothetical unlabelled drug treatments (and an opt-out option) that varied with respect to four attributes: efficacy in reducing the risk of fracture, type of potential common side effects, and mode and frequency of administration. In those countries in which patients contribute to the cost of their treatment directly, a fifth attribute was added: out-of-pocket cost. A mixed logit panel model was used to estimate patients' preferences. Results. In total, 1124 patients completed the experiment, with a sample of between 98 and 257 patients per country. In all countries, patients preferred treatment with higher effectiveness, and 6-monthly subcutaneous injection was always preferred over weekly oral tablets. In five countries, patients also preferred a monthly oral tablet and yearly i.v. injections over weekly oral tablets. In the three countries where the out-of-pocket cost was included as an attribute, lower costs significantly contributed to the treatment preference. Between countries, there were statistically significant differences for 13 out of 42 attribute/level interactions. Conclusion. We found statistically significant differences in patients' preferences for anti-osteoporosis medications between countries, especially for the mode of administration. Our findings emphasized that international treatment recommendations should allow for local adaptation, and that understanding individual preferences is important if we want to improve the quality of clinical care for patients with osteoporosis. © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. [less ▲]

Detailed reference viewed: 9 (0 ULiège)
Full Text
Peer Reviewed
See detailPotential cost-effectiveness for using patient decision aids to guide osteoporosis treatment
Penton, H; Hiligsmann, M.; Harrison, M. et al

in Osteoporosis International (2016), 27

We use a model to predict whether using a patient decision aid in patients considering bisphosphonate therapy would be a good use of health resources. We found that if the decision aid improved adherence ... [more ▼]

We use a model to predict whether using a patient decision aid in patients considering bisphosphonate therapy would be a good use of health resources. We found that if the decision aid improved adherence, and only marginally increased time physicians needed with their patients, then the decision-aid would be cost-effective. Introduction Oral bisphosphonates have been shown to reduce the risk of osteoporotic fracture. Adherence is crucial but suboptimal. A recent study suggests that a patient decision aid, which facilitates shared decision-making, could be effective in increasing adherence to bisphosphonates. But decision aids come at a cost in terms of additional time spent with physicians. This study considers the emerging evidence on the role of patient decision aids in improving adherence to bisphosphonates and their potential costs to inform future decision-making and research priorities. [less ▲]

Detailed reference viewed: 19 (2 ULiège)
Full Text
Peer Reviewed
See detailPreferences of patients for osteoporosis drug treatment: a cross-european discrete choice experiment
Hiligsmann, Mickaël ULiege; Dellaert, BG; Dirksen, CD et al

in Osteoporosis International (2014), 25(2), 227-228

Detailed reference viewed: 19 (1 ULiège)
Full Text
Peer Reviewed
See detailPatients' preferences for osteoporosis drug therapy : a discrete choice experiment
Hiligsmann, Mickaël ULiege; Dellaert, B; Dirksen, C et al

in Osteoporosis International (2013), 24(1), 53

Detailed reference viewed: 16 (4 ULiège)
Full Text
Peer Reviewed
See detailWhat are the most important medication attributes for patients with osteoporosis ? Results from a qualitative study
Hiligsmann, Mickaël ULiege; Van Durme, C; Geusens, P et al

in Osteoporosis International (2012, March), 23(S2), 81-82

Detailed reference viewed: 32 (3 ULiège)
Full Text
Peer Reviewed
See detailQuelles sont les caractéristiques des médicaments les plus importantes pour les patients ostéoporotiques ? Résultats d'une étude qualitative
Hiligsmann, Mickaël ULiege; Van Durme, C; Geusens, P et al

in Revue du Rhumatisme (2012), 79(S1), 238

Detailed reference viewed: 30 (4 ULiège)
Full Text
Peer Reviewed
See detailNominal group technique to prioritize preferences for medication attributes from the patients’ perspective : the case of osteoporosis
Hiligsmann, Mickaël ULiege; Van Durme, C; Geusens, P et al

in Annals of the Rheumatic Diseases (2012), 71(3), 597

Detailed reference viewed: 57 (5 ULiège)
Full Text
Peer Reviewed
See detailHealthcare consumption and direct costs of rheumatoid arthritis in Belgium
Westhovens, R.; Boonen, A.; Verbruggen, L. et al

in Clinical Rheumatology (2005), 24(6), 615-619

The aim of this study was to compare the socioeconomic consequences of early and late rheumatoid arthritis in Belgium and to assess the patient out-of-pocket contributions. This multicentre longitudinal ... [more ▼]

The aim of this study was to compare the socioeconomic consequences of early and late rheumatoid arthritis in Belgium and to assess the patient out-of-pocket contributions. This multicentre longitudinal study in Belgium evaluated patients with rheumatoid arthritis. Early disease was defined as diagnosis since less than 1 year. At baseline sociodemographic and disease characteristics were assessed and during the following year patients recorded all healthcare- and non-healthcare-related direct costs and out-of-pocket contributions. The study included 48 patients with early and 85 patients with late rheumatoid arthritis. Mean disease duration was 0.5 vs 12.5 years in patients with early and late rheumatoid arthritis, respectively. The disease activity score (DAS28) was comparable between both groups (4.1 vs 4.5, p=0.14), but physical function (Health Assessment Questionnaire, HAQ) was more impaired in patients with long-standing disease (1.0 vs 1.7, p < 0.001). Work disability had increased from 2% in patients with early to 18% in patients with late disease. The annual societal direct costs per patient were E 3055 (median: E 1518) opposed to E 9946 (median: E 4017) for early and late rheumatoid arthritis, respectively. The higher direct cost for patients with long-standing disease was seen for all categories, but especially for physiotherapy and need for devices and adaptations. Patients with early as well as late disease contribute out of pocket about one-third to the direct healthcare costs. Within each group, HAQ was a strong determinant of costs. In Belgium, patients with long-standing rheumatoid arthritis are nine times more likely to be work disabled than patients with less than 1 year disease duration and have a threefold increase in costs. Differences in healthcare consumption between patients could be mainly explained by differences in physical function (HAQ). [less ▲]

Detailed reference viewed: 33 (1 ULiège)
Peer Reviewed
See detailTaqI restriction fragment length polymorphism for bovine growth hormone in bovine breeds selected for milk and/or meat.
Renaville, Robert ULiege; Sneyers, Myriam; Falaki, Mohammed et al

Poster (1994)

Detailed reference viewed: 8 (0 ULiège)
Peer Reviewed
See detailTaqI restriction fragment length polymorphism for bovine growth hormone in bovine breeds selected for milk and/or meat
Renaville, Robert ULiege; Sneyers, Myriam; Falaki, Mohammed et al

Poster (1994)

Detailed reference viewed: 7 (0 ULiège)
Peer Reviewed
See detailTaqI restriction fragment length polymorphism for bovine growth hormone in bovine breeds selected for milk and/or meat
Renaville, Robert ULiege; Sneyers, Myriam; Falaki, Mohammed et al

in Journal of Animal Science (1994), 72(suppl 1), 316

Detailed reference viewed: 7 (0 ULiège)